SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-26-002458 to Adlai Nortye Ltd. (ANL)

Adlai Nortye Ltd.
Date: March 10, 2026 · CIK: 0001944552 · Accession: 0000000000-26-002458

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-294173

Date
March 10, 2026
Author
Yang Lu
Form
UPLOAD
Company
Adlai Nortye Ltd.

Letter

March 10, 2026 Yang Lu Chief Executive Officer Adlai Nortye Ltd. c/o PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands Re:Adlai Nortye Ltd. Registration Statement on Form F-3 Filed March 10, 2026 File No. 333-294173 Dear Yang Lu: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Yu Wang, Esq.

Show Raw Text
March 10, 2026
Yang Lu
Chief Executive Officer
Adlai Nortye Ltd.
c/o PO Box 309, Ugland House
Grand Cayman, KY1-1104
Cayman Islands
Re:Adlai Nortye Ltd.
Registration Statement on Form F-3
Filed March 10, 2026
File No. 333-294173
Dear Yang Lu:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Yu Wang, Esq.